ChiCTR2100052713 版本V1.0 版本创建时间2021/11/04 12:52:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052713 

最近更新日期:

Date of Last Refreshed on:

2021-11-04 12:52:27 

注册时间:

Date of Registration:

2021-11-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

耳穴疗法配合八段锦对女性强戒人员身心康复的影响

Public title:

Effect of auricular point therapy combined with Baduanjin on physical and mental recovery of female strong abstainers

注册题目简写:

English Acronym:

研究课题的正式科学名称:

耳穴疗法配合八段锦对女性强戒人员身心康复的影响

Scientific title:

Effect of auricular point therapy combined with Baduanjin on physical and mental recovery of female strong abstainers

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张鹏 

研究负责人:

苏友新 

Applicant:

Peng Zhang 

Study leader:

Youxin Su 

申请注册联系人电话:

Applicant telephone:

15090616626

研究负责人电话:

Study leader's
telephone:

13305021666

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

michael3957@163.com

研究负责人电子邮件:

Study leader's E-mail:

suyouxin777@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市闽侯上街镇福建中医药大学

研究负责人通讯地址:

福建省福州市闽侯上街镇福建中医药大学

Applicant address:

Fujian University of traditional Chinese medicine, Minhou Shangjie Town, Fuzhou City, Fujian Province

Study leader's address:

Fujian University of traditional Chinese medicine, Minhou Shangjie Town, Fuzhou City, Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建中医药大学

Applicant's institution:

Fujian University of traditional Chinese Medicine

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021KS-29-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建中医药大学附属第三附属医院

Name of the ethic committee:

The Third Affiliated Hospital of Fujian University of traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

占璐

Contact Name of the ethic committee:

Lu Zhan

伦理委员会联系地址:

福州市闽侯县上街镇国宾大道363号

Contact Address of the ethic committee:

363 Guobin Avenue, Shangjie Town, Minhou County, Fuzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

0591-22867120

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建中医药大学

Primary sponsor:

Fujian University of traditional Chinese Medicine

研究实施负责(组长)单位地址:

福建中医药大学

Primary sponsor's address:

Fujian University of traditional Chinese Medicine

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建中医药大学

具体地址:

闽侯上街镇邱阳路1号

Institution
hospital:

Fujian University of Traditional Chinese Medicine

Address:

1 Qiuyang Road, Shangjie Town, Minhou County

经费或物资来源:

福建省科技厅

Source(s) of funding:

Fujian Provincial Department of science and technology

研究疾病:

戒断综合征  

Target disease:

abstinence syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

为戒毒工作提供“简、便、廉、效”的中医方案,在帮助强戒人员早日回归社会的同时,又可以节约医疗开支和医疗资源。  

Objectives of Study:

Provide a "simple, convenient, cheap and effective" TCM scheme for drug rehabilitation, which can not only help the strong abstainers return to society as soon as possible, but also save medical expenses and medical resources

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合上述诊断标准;
(2)完成生理脱毒期,处于康复巩固期阶段;
(3)年龄15-50岁;
(4)近1-2月未接受抗焦虑或抗抑郁治疗者;
(5)能积极配合本课题研究,并按计划坚持治疗者;
(6)能理解本项研究,本人或法定监护人同意并签署知情同意书。

Inclusion criteria

(1) Meet the above diagnostic criteria;
(2) Complete the physiological detoxification stage and be in the stage of rehabilitation and consolidation; (3) Age 15-50 years;
(4) Those who have not received anti anxiety or anti depression treatment in recent 1-2 months;
(5) Those who can actively cooperate with the research of this subject and adhere to the treatment according to the plan;
(6) If I can understand this study, I or my legal guardian agree and sign the informed consent form.

排除标准:

(1)患有艾滋病者;
(2)体质极度虚弱或年老体弱或高血压3级、糖尿病控制不理想者;
(3)合并心脑血管、肝、肾、造血系统等严重疾病及精神病患者;
(4)严重精神病及神经系统疾病患者;
(5)妊娠期及哺乳期妇女;
(6)其他全身性疾病的急性期,伴有血象异常或发热者;
(7)肢体残缺、失聪者;
(8)对耳穴按压胶带过敏、无法忍受耳穴按压刺激者;
(9)正在参与其它临床试验者。

Exclusion criteria:

(1) people suffering from AIDS;
(2) physique is extremely weak or old or weak or high blood pressure 3, diabetes control is not ideal;
(3) Patients with serious diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and psychosis;
(4) Patients with severe mental and nervous system diseases;
(5) Pregnant and lactating women;
(6) Acute stage of other systemic diseases with abnormal hemogram or fever;
(7) Physically disabled and deaf;
(8) Those who are allergic to ear point pressing tape and can't stand ear point pressing stimulation;
(9) Those who are participating in other clinical trials.

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2024-11-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-01 00:00:00 To 2023-03-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

常规教育+广播体操

干预措施代码:

Intervention:

Routine education + broadcast gymnastics

Intervention code:

组别:

八段锦组

样本量:

30

Group:

Baduanjin group

Sample size:

干预措施:

常规教育+八段锦

干预措施代码:

Intervention:

Regular education + Baduanjin

Intervention code:

组别:

耳穴+八段锦组

样本量:

30

Group:

Auricular point + Baduanjin group

Sample size:

干预措施:

常规教育+耳穴+八段锦

干预措施代码:

Intervention:

Routine education + auricular points + Baduanjin

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省女子司法强制隔离戒毒所 

单位级别:

 

Institution
hospital:

Fujian women's judicial compulsory isolation rehabilitation center

Level of the institution:

测量指标:

Outcomes:

指标中文名:

血清β-内啡肽

指标类型:

主要指标

Outcome:

Serum β- endorphins

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多巴胺

指标类型:

主要指标

Outcome:

Dopamine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

去甲肾上腺素

指标类型:

主要指标

Outcome:

Norepinephrine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

5-羟色胺

指标类型:

主要指标

Outcome:

5-hydroxytryptamine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

国民体质测试

指标类型:

主要指标

Outcome:

National physical fitness test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心理健康自评量表

指标类型:

主要指标

Outcome:

Mental health self-rating scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评表

指标类型:

主要指标

Outcome:

Anxiety self-rating scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠自评表

指标类型:

主要指标

Outcome:

PSQI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

药物渴求度等量表

指标类型:

主要指标

Outcome:

Drug craving scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age 50 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

根据随机数字表化将受试者分入对照组、八段锦组、耳穴+八段锦组,三组受试者例数比为1:1:1。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the random number table, the subjects were divided into control group, Baduanjin group and auricular point + Baduanjin group. The number ratio of subjects in the three groups was 1:1:1.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-04 12:52:27